DNER and neoplasm: Recently, a novel prognostic model of NC has confirmed the substantially shorter overall survival of thoracic compared with nonthoracic tumours, irrespective of the fusion partner expressed, whereas nonthoracic tumours may be subdivided, with longer survival documented among patients with tumours harbouring non-BRD4 fusions.37 Thus, in this study, clinical benefit was observed with BET inhibition among patients with NC carrying the worst prognosis.